Sep 30, 2025 • Benzinga
NEUTRAL
Price Over Earnings Overview: Insulet - Insulet ( NASDAQ:PODD )
Looking into the current session, Insulet Inc. ( NASDAQ:PODD ) shares are trading at $306.78, after a 1.24% drop. Over the past month, the stock fell by 11.06%, but over the past year, it actually spiked by 31.87%.
Sep 29, 2025 • Benzinga
SOMEWHAT-BULLISH
Here's How Much $100 Invested In Insulet 15 Years Ago Would Be Worth Today - Insulet ( NASDAQ:PODD )
Insulet ( NASDAQ: PODD ) has outperformed the market over the past 15 years by 10.02% on an annualized basis producing an average annual return of 22.35%. Currently, Insulet has a market capitalization of $21.87 billion.
Sep 29, 2025 • Zacks Commentary
BULLISH
Why Insulet ( PODD ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Sep 26, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Insulet Stock Surges 37.4% in 12 months: What's Driving the Rally?
PODD stock rallies 37.4% in a year, fueled by Omnipod 5 adoption, global launches and expanding reach in diabetes care.
Sep 19, 2025 • Benzinga
SOMEWHAT-BULLISH
Here's How Much $100 Invested In Insulet 10 Years Ago Would Be Worth Today - Insulet ( NASDAQ:PODD )
Insulet PODD has outperformed the market over the past 10 years by 14.5% on an annualized basis producing an average annual return of 27.65%. Currently, Insulet has a market capitalization of $23.29 billion.
Sep 19, 2025 • Benzinga
NEUTRAL
Spotlight on DexCom: Analyzing the Surge in Options Activity - DexCom ( NASDAQ:DXCM )
Deep-pocketed investors have adopted a bearish approach towards DexCom DXCM, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.